What is Michelson Diagnostics?
Founded in 2006, Michelson Diagnostics is a specialized provider of Optical Coherence Tomography (OCT) systems, a technology that has become synonymous with high-precision skin imaging. The company's flagship product, the VivoSight Dx Pro, provides clinicians and researchers with non-invasive, real-time visualization of skin structures. With over 700 peer-reviewed publications validating its methodology, the company has established itself as a leader in the diagnostic imaging space. By focusing on the intersection of clinical dermatology and advanced photonics, Michelson Diagnostics addresses the critical need for accurate, fast, and accessible skin health assessment tools, effectively positioning itself as an essential partner for dermatologists and research institutions worldwide.
How much funding has Michelson Diagnostics raised?
Michelson Diagnostics has raised a total of $7.1M across 2 funding rounds:
Series A
$3.3M
Series B
$3.8M
Series A (2014): $3.3M with participation from Turner Investments and Catapult Venture Managers Ltd
Series B (2015): $3.8M led by Turner Investments and Catapult Venture Managers Ltd
Key Investors in Michelson Diagnostics
Turner Investments
Turner Investments specializes in providing comprehensive financial research and insights aimed at helping investors make informed decisions across various asset classes.
Catapult Venture Managers Ltd
Catapult Ventures focuses on providing tailored investment solutions and strategic partnerships to support the growth and value creation of entrepreneurial ventures.
What's next for Michelson Diagnostics?
With the recent strategic investment, Michelson Diagnostics is well-positioned to accelerate its commercialization efforts and deepen its penetration into international clinical markets. The company is expected to prioritize the expansion of its R&D pipeline, focusing on enhancing the diagnostic accuracy and user interface of its OCT systems. Furthermore, the firm will likely leverage this capital to strengthen its distribution networks and support ongoing clinical trials, which are vital for maintaining its competitive edge in the rapidly evolving medical imaging landscape. As the demand for non-invasive diagnostic procedures continues to rise, Michelson Diagnostics remains focused on scaling its infrastructure to meet the needs of a growing global client base, ensuring that its innovative technology remains at the forefront of dermatological care.
See full Michelson Diagnostics company page
